-

CureDuchenne Announces Initiative For Free Medical ID Bracelets to Individuals With Duchenne

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--CureDuchenne, a leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, announced today a new initiative to deliver free medical ID bracelets to individuals in the United States living with Duchenne.

With an initial limited quantity of 1,200 bracelets supplied by MyID, a leading provider of medical bracelets, they will be distributed on a first-come-first-serve basis. Each bracelet is associated with a customizable user profile that comes prefilled with emergency information written specifically for individuals living with Duchenne.

“2020 has come with many challenges, so we are excited to offer our community a special gift of ‘peace of mind’ for the holidays this year,” said Debra Miller, Founder and CEO, CureDuchenne. “These bracelets could prove lifesaving for our community. Emergency professionals and first responders will be able to have easy and quick access to information about Duchenne. We can’t always be with our boys, so knowing that if something does happen, the ones that help them first will have this knowledge is crucial.”

Bracelets can be ordered online directly from CureDuchenne’s website at: https://www.cureduchenne.org/medical-id-bracelets/

About CureDuchenne

CureDuchenne is recognized as a global leader in research, patient care, and innovation for improving and extending the lives of those with Duchenne muscular dystrophy. As the leading genetic killer of young boys, Duchenne affects more than 300,000 individuals living today. CureDuchenne is dedicated to finding and funding a cure for Duchenne by breaking the traditional charitable mold through an innovative venture philanthropy model that funds groundbreaking research, early diagnosis, and community education. For more information on how to help raise awareness and funds needed for research, please visit www.cureduchenne.org.

Contacts

Brandon Tarnow
info@cureduchenne.org
(949) 872-2552

CureDuchenne


Release Versions

Contacts

Brandon Tarnow
info@cureduchenne.org
(949) 872-2552

Social Media Profiles
More News From CureDuchenne

CureDuchenne Congratulates Pfizer on Dosing First Patient in Phase III Clinical Trial for Duchenne Muscular Dystrophy

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--CureDuchenne, a leading global nonprofit dedicated to finding and funding a cure for Duchenne muscular dystrophy (DMD), celebrates Pfizer Inc’s (NYSE: PFE) announcement surrounding the first dosing of a patient with Duchenne in their Phase III gene therapy clinical trial. Pfizer has showcased tremendous progress over the past year in pushing forward PF-06939926, its rAAV9 mini-dystrophin gene therapy for DMD. PF-06939926 was initially developed by Jude Sa...

CureDuchenne Applauds Pfizer’s Encouraging Data from Phase Ib Mini-Dystrophin Gene Therapy Trial for Duchenne Muscular Dystrophy

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--CureDuchenne, a leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, congratulates Pfizer for announcing data from subjects that have completed the 12 month Phase Ib clinical trial presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. Today’s announcement included updates on the safety and efficacy data from muscle biopsies and the North Star Ambulatory Assessments (NSAA) for the 9...

Myosana Therapeutics, Inc. Raises Up To $1M from CureDuchenne Ventures

NEWPORT BEACH, Calif. & SEATTLE--(BUSINESS WIRE)--Myosana Therapeutics, Inc., a new biotech company developing novel platform technology for non-viral gene delivery, raised up to $1M in seed financing from CureDuchenne Ventures. Myosana will use this initial funding to advance development of its innovative non-viral gene therapy to deliver full length dystrophin for Duchenne muscular dystrophy (DMD). Myosana Therapeutics was founded in 2018 by University of Washington School of Medicine faculty...
Back to Newsroom